Study of NM8074 for Dermatomyositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a body mass index (BMI) between 15 and 38.
- You must have a confirmed diagnosis of dermatomyositis based on standard criteria.
- You must have received certain vaccines (meningitis, pneumonia, and Hib) at least 2 weeks before the study starts, or agree to take preventive antibiotics.
- If you are able to have children, you must use effective birth control during the study and for 8 weeks after the last dose.
- You cannot have certain medical conditions like active infections, cancer in the past 5 years, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy (PN-101) made from donated mitochondria, which are tiny energy-producing parts of cells. It is for adults with refractory (hard-to-treat) polymyositis or dermatomyositis. The goal is to see if PN-101 can improve muscle strength and reduce disease activity.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.